1 week Ago By Defense World Staff
Sei Investments Co. bought a new position in Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The firm bought 61,140 shares of the company’s stock, valued at approximately $95,000. Sei Investments Co. owned about 0.
10% of Pyxis Oncology as of its most recent SEC filing. A number of other hedge funds and other institutional investors also recently bought and sold shares of PYXS. Commonwealth Equity Services LLC lifted its holdings in shares of Pyxis Oncology by 61.
5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after purchasing an additional 10,000 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Pyxis Oncology in the third quarter worth $107,000.
Jane Street Group LLC lifted its stake in Pyxis Oncology by 40.8% in the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after buying an additional 14,349 shares during the last quarter.
Barclays PLC lifted its stake in Pyxis Oncology by 275.0% in the third quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after buying an additional 46,997 shares during the last quarter.
Finally, XTX Topco Ltd boosted its holdings in shares of Pyxis Oncology by 133.6% during the third quarter. XTX Topco Ltd now owns 84,771 shares of the company’s stock valued at $311,000 after acquiring an additional 48,481 shares during the period.
39.09% of the stock is currently owned by institutional investors and hedge funds. Pyxis Oncology Stock Up 5.
7 %Shares of Pyxis Oncology stock opened at $0.96 on Friday. The business has a fifty day simple moving average of $1.
14 and a 200-day simple moving average of $2.05. Pyxis Oncology, Inc.
has a fifty-two week low of $0.83 and a fifty-two week high of $5.39.
The firm has a market cap of $59.05 million, a price-to-earnings ratio of -0.93 and a beta of 1.
17. Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.
32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01.
The business had revenue of $16.15 million during the quarter. Analysts anticipate that Pyxis Oncology, Inc.
will post -1.04 earnings per share for the current fiscal year. Wall Street Analyst Weigh InA number of research firms recently weighed in on PYXS.
Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Pyxis Oncology in a report on Wednesday, March 19th. HC Wainwright restated a “buy” rating and issued a $5.
00 price target on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.
com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.20.Read Our Latest Stock Report on PYXSPyxis Oncology Company Profile (Free Report)Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers.
Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.Further ReadingFive stocks we like better than Pyxis OncologyBank Stocks – Best Bank Stocks to Invest InRobinhood Strategies Could Be a Game-Changer for Young InvestorsGrowth Investing: Should You Adopt This Investing Strategy in 2022?Are These 3 Retail Stocks Oversold or Really in Trouble?3 Grocery Stocks That Are Proving They Are Still Essential IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadWant to see what other hedge funds are holding PYXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pyxis Oncology, Inc.
(NASDAQ:PYXS – Free Report)..
